Allergic rhinitis (AR) is one of the most prevalent medical conditions. It has significant effects on quality of life and can have considerable socioeconomic effects.
The traditional classification of perennial and seasonal rhinitis does not distinguish between provoking factors, nor does it indicate the most appropriate treatment. A more useful classification is based on symptoms, which may be intermittent or persistent, and vary widely in severity.
The goal of management is to achieve optimal symptom control. Therapeutic options include allergen avoidance, pharmacotherapy and immunotherapy.
Antihistamines and intranasal corticosteroids (INCS) have become the cornerstones of therapy. A variety of effective treatments are available for consumers to self-select, without the advice of a doctor or pharmacist.
INCS are widely recognised as the most effective pharmacotherapy for AR, in both adults and children. The efficacy of various preparations is similar, but those with low systemic bioavailability are preferred for children and for patients who are also receiving inhaled, topical or systemic corticosteroids.
- 1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-S334.
- 2. Hopper JL, Jenkins MA, Carlin JB, Giles GG. Increase in the self-reported prevalence of asthma and hay fever in adults over the last generation: a matched parent-offspring study. Aust J Public Health 1995; 19: 120-124.
- 3. Australian Institute of Health and Welfare GP Statistics and Classification Unit. SAND abstract No.1 from the BEACH program: Allergic rhinitis. Sydney: GPSCU University of Sydney; 2000. Available at: www.fmrc.org.au/allergicrhinitis.pdf (accessed Feb 2004).
- 4. Robertson CF, Dalton MF, Peat JK, et al. Asthma and other atopic diseases in Australian children. Australian arm of the International Study of Asthma and Allergy in Childhood. Med J Aust 1998; 168: 434-438. <MJA full text>
- 5. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002; 88: 2-7.
- 6. Australian Institute of Health and Welfare. Health expenditure Australia 2001–02. Health and Welfare Expenditure Series no. 17. Canberra: AIHW; 2003. (AIHW Catalogue no. HWE 24.)
- 7. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109: 419-425.
- 8. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994; 15: 21-25.
- 9. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106(5 Suppl): 201-205.
- 10. Fuhlbrigge AL, Adams RJ. The effect of treatment of allergic rhinitis on asthma morbidity, including emergency department visits. Curr Opin Allergy Clin Immunol 2003; 3: 29-32.
- 11. Mucha SM, Baroody FM. Relationships between atopy and bacterial infections. Curr Allergy Asthma Rep 2003; 3: 232-237.
- 12. Naclerio R. Clinical manifestations of the release of histamine and other inflammatory mediators. Allergy Clin Immunol 1999; 103: 382-385.
- 13. Puy R. Diagnosing and treating allergic rhinitis. Med Today 2003; 4: 14-22.
- 14. Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis: a systematic review of efficacy. Br J Gen Pract 2003; 53: 318-322.
- 15. Gotzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. BMJ 1998; 317: 1105-1110.
- 16. Rijssenbeek-Nouwens LH, Oosting AJ, Bruin-Weller MS, et al. Clinical evaluation of the effect of anti-allergic mattress covers in patients with moderate to severe asthma and house dust mite allergy: a randomised double blind placebo controlled study. Thorax 2002; 57: 784-790.
- 17. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116-134.
- 18. Dykewicz MS, Fineman S. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478-518.
- 19. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317: 1624-1629.
- 20. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89: 479-484.
- 21. Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines. Am J Manag Care 1998; 4: 89-96.
- 22. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than the other? J Laryngol Otol 2003; 117: 843-845.
- 23. Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000; 106 Suppl 4: 179-190.
- 24. Simons FE. Non-cardiac adverse effects of antihistamines (H1-receptor antagonists). Clin Exp Allergy 1999; 29 Suppl 3: 125-132.
- 25. Australian Medicines Handbook. 5th ed. Adelaide: Australian Medicines Handbook Ltd, 2004.
- 26. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949-955.
- 27. Bousquet J, Lund VJ, Van Cauwenberge P, et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003; 58: 733-741.
- 28. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medications in the preschool and young school-age child: what are the options? BioDrugs 2001; 15: 453-463.
- 29. Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol 2001; 108: S59-S64.
- 30. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90: 56-62.
- 31. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: e22.
- 32. Moller C, Ahlstrom H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003; 33: 816-822.
- 33. Richards DH, Milton CM. Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis. Pediatr Allergy Immunol 1996; 7: 35-43.
- 34. Simons FE, Fraser TG, Reggin JD, et al. Adverse central nervous system effects of older antihistamines in children. Pediatr Allergy Immunol 1996; 7: 22-27.
- 35. Simons FE, Reggin JD, Roberts JR, Simons KJ. Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. J Pediatr 1994; 124: 979-983.
- 36. Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Specific allergen immunotherapy for asthma. Med J Aust 1997; 167: 540-544. <MJA full text>
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.